Gossamer Bio, Inc.

NasdaqGS:GOSS 주식 리포트

시가총액: US$46.7m

Gossamer Bio 향후 성장

Future 기준 점검 5/6

Gossamer Bio은 연간 수입과 매출이 각각 66.8%와 44.6% 증가할 것으로 예상되고 EPS는 연간 69.8%만큼 증가할 것으로 예상됩니다.

핵심 정보

66.8%

이익 성장률

69.82%

EPS 성장률

Biotechs 이익 성장25.5%
매출 성장률44.6%
향후 자기자본이익률n/a
애널리스트 커버리지

Good

마지막 업데이트20 May 2026

최근 향후 성장 업데이트

Recent updates

내러티브 업데이트 • May 09

GOSS: Upcoming FDA Talks On Phase 3 Data Will Drive Potential Rerating

Narrative Update Gossamer Bio's analyst price targets have been reset sharply lower, with cuts from as high as $12 to as low as $0.30. Analysts are factoring in weaker than expected Phase 3 PROSERA data, a clouded regulatory path for seralutinib in pulmonary arterial hypertension, and added balance sheet and funding uncertainties.
내러티브 업데이트 • Apr 22

GOSS: Upcoming FDA Meeting Will Determine Potential Rerating After Phase 3 Setback

Analysts have lowered their average price targets on Gossamer Bio into the low single-digit dollar range, reflecting reduced modeled revenue growth, a higher discount rate, and increased regulatory uncertainty around seralutinib following the recent Phase 3 PROSERA miss and multiple rating downgrades. Analyst Commentary Recent Street research around Gossamer Bio clusters around two themes: how to weigh the mixed seralutinib data against the regulatory risk, and how to factor balance sheet constraints into valuation.
내러티브 업데이트 • Apr 07

GOSS: Regulatory Path And Funding Outlook Will Shape Future Repricing Potential

Narrative Update: Gossamer Bio The average analyst price target for Gossamer Bio has moved sharply lower into the low single digits, with firms citing reduced probabilities of success for seralutinib in pulmonary arterial hypertension, a mixed Phase 3 PROSERA outcome that missed its primary endpoint, and added regulatory and funding uncertainty as key drivers behind the reset. Analyst Commentary Recent Street research around Gossamer Bio has turned more cautious, with several bearish analysts reacting to the Phase 3 PROSERA miss, regulatory uncertainty for seralutinib in pulmonary arterial hypertension, and funding needs.
내러티브 업데이트 • Mar 24

GOSS: Regulatory Meetings On Phase 3 Miss Will Drive Future Rerating Potential

Narrative Update The analyst price target for Gossamer Bio has been reduced, with fair value moving from $15.00 to about $13.43 as analysts factor in a lower assumed probability of success for seralutinib in pulmonary arterial hypertension, heightened regulatory uncertainty after the Phase 3 PROSERA miss, and balance sheet concerns. These factors are partially offset by ongoing expectations for higher revenue growth, stronger profit margins, and a lower future P/E multiple.
내러티브 업데이트 • Mar 08

GOSS: Upcoming FDA Meeting And 2026 Data Readouts Will Drive Rerating Potential

Analysts have sharply reduced their average price targets on Gossamer Bio, cutting them from a prior fair value indication of about $9.50 to roughly $3.69. This change reflects reduced confidence in seralutinib's regulatory path and a reevaluation of risk after the PROSERA Phase 3 miss.
내러티브 업데이트 • Feb 21

GOSS: Index Additions And Barclays Bullish Coverage Will Support Future Repricing

Analysts have raised their price target on Gossamer Bio to $6.00, citing new bullish coverage that outlines the company’s updated assumptions for risk, growth, margins and future P/E, while maintaining their fair value estimate at $6.00. Analyst Commentary While the updated price target of US$6.00 reflects a constructive view on Gossamer Bio, some research commentary also highlights areas where expectations could be tested.
내러티브 업데이트 • Feb 07

GOSS: Index Additions And Bullish Research Coverage Will Support Future Repricing

Analysts have adjusted their price target for Gossamer Bio to US$6.00, with the updated view supported by slightly revised assumptions on discount rate, revenue growth, profit margin and future P/E following fresh bullish Street research coverage. Analyst Commentary While the updated US$6.00 price target reflects constructive views in recent research, not all commentators are aligned with the bullish tone.
내러티브 업데이트 • Jan 23

GOSS: Index Additions And February 2026 Data Will Drive Rerating Potential

Analysts have maintained their fair value estimate for Gossamer Bio at US$9.50 per share. They explained that only modest adjustments to assumptions such as the discount rate and future P/E were required, and these did not affect their overall price target view.
분석 기사 • Jan 22

Gossamer Bio, Inc.'s (NASDAQ:GOSS) Popularity With Investors Under Threat As Stock Sinks 27%

The Gossamer Bio, Inc. ( NASDAQ:GOSS ) share price has softened a substantial 27% over the previous 30 days, handing...
내러티브 업데이트 • Jan 09

GOSS: Index Additions And Updated Assumptions Will Support Bullish Repricing

Analysts have revised their price target on Gossamer Bio to US$6.00, with the unchanged fair value level tied to updated assumptions that include adjusted discount rates, a higher modeled revenue growth rate of 59.16% and a lower future P/E of about 63.33x. These factors together shape their latest view of the share price outlook.
Seeking Alpha • Dec 19

Gossamer Bio: High-Risk Binary Approaches

Summary Gossamer Bio is approaching a binary catalyst with the February 2026 PROSERA phase 3 readout for seralutinib in pulmonary arterial hypertension. PROSERA differs from the phase 2 TORREY study, by focusing on 6MWD as the primary endpoint, enrolling higher-risk patients and more patients outside North America. GOSS is also running a trial of seralutinib in those with pulmonary hypertension associated with interstitial lung disease. That trial only got underway in Q4 '25, however. Read the full article on Seeking Alpha
내러티브 업데이트 • Dec 14

GOSS: Upcoming Respiratory Congress Data Will Likely Drive Stronger Market Reassessment

Analysts have sharply raised their price target on Gossamer Bio, with fair value estimates climbing from approximately 1.25 to 6.00 per share. They cite expectations for significantly faster revenue growth and a higher future earnings multiple, despite a modest uptick in discount rates and slightly lower projected profit margins.
내러티브 업데이트 • Nov 28

GOSS: Improving Market Conviction Will Drive Momentum Into February 2026 Data Release

Analysts have maintained their price target for Gossamer Bio at $9.50 per share, citing increasingly positive sentiment and renewed conviction about seralutinib’s outlook as key clinical milestones approach. Analyst Commentary As key clinical milestones for seralutinib approach, analysts have weighed in with both optimistic and cautious perspectives regarding Gossamer Bio’s future prospects and current valuation.
분석 기사 • Nov 25

Gossamer Bio, Inc.'s (NASDAQ:GOSS) 28% Share Price Surge Not Quite Adding Up

Gossamer Bio, Inc. ( NASDAQ:GOSS ) shareholders have had their patience rewarded with a 28% share price jump in the...
내러티브 업데이트 • Nov 14

GOSS: Improving Sentiment Will Drive Momentum Ahead of February 2026 Data Readout

Analysts have raised their price target for Gossamer Bio from $8.86 to $9.50. They cite increased conviction in the company's upcoming clinical data and improving market sentiment around its lead drug candidate.
분석 기사 • Oct 11

Gossamer Bio, Inc. (NASDAQ:GOSS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Gossamer Bio, Inc. ( NASDAQ:GOSS ) shares have retraced a considerable 27% in the last month, reversing a fair amount...
내러티브 업데이트 • Sep 11

Phase III Trials And Global Collaborations Will Expand Treatment Horizons

Analysts have raised their price target for Gossamer Bio from $7.75 to $8.86, citing optimism for seralutinib's novel mechanism and market potential in pulmonary hypertension as key drivers. Analyst Commentary Positive outlook on Gossamer Bio's strategy in targeting pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
분석 기사 • Aug 22

Revenues Not Telling The Story For Gossamer Bio, Inc. (NASDAQ:GOSS) After Shares Rise 26%

Despite an already strong run, Gossamer Bio, Inc. ( NASDAQ:GOSS ) shares have been powering on, with a gain of 26% in...
User avatar
새로운 내러티브 • May 18

Phase III Trials And Global Collaborations Will Expand Treatment Horizons

Successful Phase III study enrollment and collaboration enhance market reach, promising revenue growth through potential positive efficacy results and expanded indications.
Seeking Alpha • Feb 14

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Summary Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far produced encouraging Phase 2 data and has an ongoing Phase 3 PROSERA trial for PAH. The main event comes with its topline results in Q4 2025. GOSS’s pipeline includes a PH-ILD program slated to start Phase 3 in mid-2025. This program addresses a larger, high-mortality TAM. Lastly, Gossamer Bio seems to have enough resources to fund both of these trials in 2025. So, I believe its cash runway is sufficient for now. In my view, GOSS is now basically a binary bet on the upcoming Phase 3 data by the end of the year, and for now, it looks reasonably priced relative to its upside potential. Read the full article on Seeking Alpha
Seeking Alpha • Sep 10

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Summary Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and systemic absorption issues, unlike seralutinib, which targets key disease pathways effectively. Tyvaso DPI's success in PH-ILD highlights the unmet need, with Gossamer planning a Phase 3 trial for seralutinib in mid-2025. Seralutinib's potential in PH-ILD and PAH, combined with its safety profile, positions it as a strong contender in the biopharmaceutical market. Read the full article on Seeking Alpha
분석 기사 • Aug 14

Brokers Are Upgrading Their Views On Gossamer Bio, Inc. (NASDAQ:GOSS) With These New Forecasts

Shareholders in Gossamer Bio, Inc. ( NASDAQ:GOSS ) may be thrilled to learn that the analysts have just delivered a...
Seeking Alpha • Sep 27

Peaking Back In On Gossamer Bio

Summary Today, we look back in on a small biotech company called Gossamer Bio. The company's primary drug candidate is approaching a key trial milestone and analyst firms are currently sanguine on Gossamer's long-term prospects. An investment analysis follows in the paragraphs below. A humble man speaks not of his own humility" - Jeremy Aldana Today, we are shining the spotlight back on Gossamer Bio (GOSS) for the first time since our last article on this small biotech name back in October of last year. The stock trades almost exactly where it was during our last look at it, which given the carnage in the markets here in 2022, counts as a victory. The shares had some insider buying in July within a private placement. No one else on Seeking Alpha has touched on the company since we last revisited it. In addition, the stock has had a wild ride in recent months. Therefore, it seems to be a good time to incorporate developments in 2022 and update our take on Gossamer. An analysis follows below. Seeking Alpha Company Overview: Gossamer Bio is clinical-stage biopharmaceutical concern focused on the development or procurement of therapies in the areas of immunology, inflammation, and oncology. The company is based in San Diego and the stock currently trades at around $12.00 a share and sports an approximate market cap of $1.1 billion. Recent Developments: August Company Presentation The company has a couple of pipeline assets in development. The most important of which is a compound called seralutinib which is also known as GB002. This candidate is targeting Pulmonary Arterial Hypertension, commonly known as PAH. The condition is a function of abnormal cell growth within and around small blood vessels of the lung that move blood from the right side of the heart to the lungs. Despite products on the market to treat this condition, the five-year survival rate is just over 55%. August Company Presentation Seralutinib has Orphan Drug status both in Europe and U.S. for this indication. This candidate is an inhaled inhibitor of the following tyrosine kinases: platelet-derived growth factor receptors α and β (PDGFRs), colony-stimulating factor 1 receptor (CSF1R), and c-KIT. It is designed to treat PAH as described in the slide above. August Company Presentation Currently, seralutinib is being evaluated in a Key Phase 2 trial called Torrey. This is a clinical study in patients with PAH whose disease has progressed despite standard-of-care therapy. The primary endpoint of this trial is the change in pulmonary vascular resistance from baseline at week 24. Topline results are scheduled to be out anywhere from the back half of November or first half of December of this year. August Company Presentation Last week, Wedbush reiterated their Buy rating on GOSS. The analyst there noted: This mid-stage trial has a high likelihood of success due to seralutinib's mechanism of action and positive results in both the preclinical and early-stage studies." She further stated that she 'believes that seralutinib has the potential to capture 42% of the market in the U.S. in 2030 with projected sales of $2.5B, assuming that the drug is launched in 2026.' August Company Presentation The company has a couple of other earlier staged assets in development. The only out of the clinic is GB5121. This is an oral, CNS-Penetrant BTK Inhibitor that is targeting Primary CNS Lymphoma (PCNSL) and other Rare CNS Malignancies. Currently, an open-label Phase 1b/2 study 'STAR' is underway to evaluate GB5121 for these indications. That study recently dosed its first patient. Management has stated that data from STAR will be presented at relevant medical conferences, as data become available. August Company Presentation Analyst Commentary & Balance Sheet: The company ended the second quarter with just over $220 million in cash and marketable securities on its balance sheet after posting a net loss for the quarter of $56.5 million. Two weeks after the quarter closed, management executed a private placement that raised an additional $120 million in proceeds. Four insiders including the CEO and CFO bought nearly $1.2 million in total of the private placement in mid-July. Up to that point, insiders had sold approximately $600,000 worth of shares in aggregate in 2022. Just over 20% of the outstanding float in GOSS is currently held short. The company has just over $200 million in long-term debt.
Seeking Alpha • Jul 13

Gossamer Bio to raise $120M in a private equity placement

Gossamer Bio (NASDAQ:GOSS) to sell approximately 16.6M shares of its common stock at $7.21/share in a private placement. Gross proceeds are expected to be approximately $120M. The financing is expected to close on July 15. “We are very pleased this high-quality group of investors came together to support the seralutinib program at this important juncture,” said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer. “These additional funds will allow us to accelerate and expand our investment in seralutinib ahead of the Phase 2 TORREY Study topline results in the fourth quarter of this year.” In addition to supporting the seralutinib program, the company intends to use the net proceeds to fund research and development of its other product candidates and development programs and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash, cash equivalents and marketable securities, and access to its debt facility is expected to be sufficient to fund operating and capital expenditures into mid-2024.
분석 기사 • Jun 25

Health Check: How Prudently Does Gossamer Bio (NASDAQ:GOSS) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Jan 19

Gossamer Bio (NASDAQ:GOSS) Has Debt But No Earnings; Should You Worry?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
분석 기사 • Sep 22

Is Gossamer Bio (NASDAQ:GOSS) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
분석 기사 • Jan 28

Need To Know: Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Have Been Buying Shares

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

이익 및 매출 성장 예측

NasdaqGS:GOSS - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/20281324-35-355
12/31/202752-60-61-616
12/31/202634-146-64-645
3/31/202656-180-170-170N/A
12/31/202548-170-171-171N/A
9/30/202544-156-159-158N/A
6/30/202540-139-154-154N/A
3/31/2025125-5199N/A
12/31/2024115-57-3-3N/A
9/30/2024105-72-1-1N/A
6/30/202496-81-4-4N/A
3/31/2024N/A-173-158-158N/A
12/31/2023N/A-180-159-159N/A
9/30/2023N/A-187-174-173N/A
6/30/2023N/A-207-176-176N/A
3/31/2023N/A-221-187-187N/A
12/31/2022N/A-229-188-187N/A
9/30/2022N/A-230-180-180N/A
6/30/2022N/A-231-186-185N/A
3/31/2022N/A-234-184-183N/A
12/31/2021N/A-234-191-189N/A
9/30/2021N/A-242-192-185N/A
6/30/2021N/A-240-195-188N/A
3/31/2021N/A-247-205-183N/A
12/31/2020N/A-243-201-176N/A
9/30/2020N/A-233-205-184N/A
6/30/2020N/A-224-197-175N/A
3/31/2020N/A-202-178-169N/A
12/31/2019N/A-180N/A-145N/A
9/30/2019N/A-164N/A-126N/A
6/30/2019N/A-165N/A-105N/A
3/31/2019N/A-154N/A-75N/A
12/31/2018N/A-147N/A-51N/A
9/30/2018N/A-115N/A-32N/A
6/30/2018N/A-66N/A-16N/A
3/31/2018N/A-33N/A-9N/A
12/31/2017N/A-7N/A-6N/A

애널리스트 향후 성장 전망

수입 대 저축률: GOSS 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: GOSS (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: GOSS 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: GOSS 의 수익(연간 44.6%)이 US 시장(연간 11.6%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: GOSS 의 수익(연간 44.6%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: GOSS의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/20 20:00
종가2026/05/20 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Gossamer Bio, Inc.는 22명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Carter GouldBarclays
Eliana MerleBarclays
Zhilin LongBerenberg